Altimmune (ALT) EBT (2010 - 2026)
Altimmune (ALT) posted quarterly EBT of -$22.6 million for Q1 2026, down 11.39% year-over-year from -$25.5 million in Q1 2025, and down 138.98% quarter-over-quarter from $57.9 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) EBT (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported EBT for 17 consecutive years, with -$22.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 11.39% year-over-year to -$22.6 million; the TTM figure through Mar 2026 stood at -$5.8 million (up 93.58% YoY), while the FY2025 annual figure was -$3.5 million, up 96.29% from the prior year.
- EBT eased to -$22.6 million in Q1 2026 per ALT's latest filing, from $57.9 million in the prior quarter.
- Across five years, EBT topped out at $57.9 million in Q4 2025 and bottomed at -$31.6 million in Q4 2023.
- Historically, EBT has averaged -$16.7 million across 5 years, with a median of -$20.7 million in 2023.
- Annual changes were most pronounced in 2023 — EBT plunged 233.06% — and 2025, when it jumped 349.74%.
- Altimmune's EBT stood at -$9.5 million in 2022, then slumped by 233.06% to -$31.6 million in 2023, then climbed by 26.74% to -$23.2 million in 2024, then surged by 349.74% to $57.9 million in 2025, then tumbled by 138.98% to -$22.6 million in 2026.
- Business Quant data shows ALT's EBT at -$22.6 million in Q1 2026, $57.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.43 Bn | 131.58 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.59 Bn | 77.59 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.44 Bn | 58.26 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.54 Bn | 52.40 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.01 Bn | 34.91 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.18 Bn | 31.87 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.35 Bn | 26.18 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Altimmune | 612.89 Mn | 612.89 Mn | - | -22.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.83 Mn |
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | -27.36 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -20.26 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | -21.66 Mn |
| Sep 30, 2022 | -23.71 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |